← Back to Search

Stem Cell Therapy

hematopoietic stem cell infusion for Sandhoff Disease

Phase 1 & 2
Waitlist Available
Research Sponsored by Talaris Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new way to give stem cell transplants that may help prevent GVHD while still being effective.

Eligible Conditions
  • Sandhoff Disease
  • Mucopolysaccharidosis I
  • Mucopolysaccharidosis II
  • Sanfilippo Syndrome
  • Alpha-Mannosidosis
  • Mucopolysaccharidosis
  • Krabbe Disease
  • ALD
  • Metachromatic Leukodystrophy
  • Tay Sachs Disease
  • PMD
  • Niemann-Pick Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Inherited Metabolic Disorder PatientsExperimental Treatment1 Intervention
Recipients are treated with hematopoietic stem cell infusion from living donors

Find a Location

Who is running the clinical trial?

Talaris Therapeutics Inc.Lead Sponsor
11 Previous Clinical Trials
99 Total Patients Enrolled
Duke UniversityOTHER
2,456 Previous Clinical Trials
2,971,497 Total Patients Enrolled
Suzanne T Ildstad, MDStudy DirectorTalaris Therapeutics Inc.
6 Previous Clinical Trials
100 Total Patients Enrolled
~0 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top